Company news

Avacta Group PLC news in 2025

Avacta Group PLC's news releases, calls and decks from 2025, newest first.

View company

Avacta reports new AVA6103 pharmacology data

December 18, 2025

Faridoxorubicin Phase 1b SGC data

December 17, 2025

Faridoxorubicin (AVA6000) Phase 1b cohort demonstrates clinically meaningful tumor shrinkage in patients with salivary gland cancers

December 17, 2025

Preliminary Data in Faridoxorubicin Phase 1b Trial

December 8, 2025

Completion of Placing and TVR

November 3, 2025

Block Listing Six Monthly Return

October 27, 2025

Avacta presents preclinical data at AACR-NCI-EORTC

October 27, 2025

Avacta presents first preclinical data from dual payload pre|CISION® medicines at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets

October 25, 2025

Notice of Investor Presentation

October 23, 2025

Equity fundraise of £16 million

October 20, 2025

Avacta Presents Phase 1a Data for Faridoxorubicin

October 20, 2025

Avacta Therapeutics Presents Compelling Phase 1a Data for Faridoxorubicin and the pre|CISION® Platform at the European Society of Medical Oncology Annual Congress

October 19, 2025

Avacta to Present First Dual Payload pre|CISION® Medicines Data at the 2025 EORTC-NCI-AACR International Conference on Molecular Targets Symposium

October 13, 2025

Avacta to present data at EORTC-NCI-AACR

October 13, 2025

Interim Half Year Results 2025

September 30, 2025

Notice of Interim Results

September 15, 2025

Shortlisted for AIM Awards Technology of the Year

September 9, 2025

Avacta completes sale of Coris Bioconcept

September 1, 2025

Amendments to Convertible Bond + equity fundraise

August 29, 2025

Avacta to Present New FAP Dox (AVA6000) Data at the European Society for Medical Oncology (ESMO) Congress

July 30, 2025

Avacta to Present at ESMO Congress

July 30, 2025

Agreement to Sell Coris Bioconcept SRL

July 28, 2025

Payment of Convertible Bond Installment

July 21, 2025

Equity fundraise of £3.25 million

July 17, 2025

Result of AGM

July 2, 2025

Q2 2025 Business Update

July 2, 2025

Management Team Appointments

July 1, 2025

Avacta Appoints David Liebowitz, M.D., Ph.D. as Chief Medical Officer and Yulii Bogatyrenko as Advisor in Business Development

July 1, 2025

Appointment of Zeus Capital as Joint Broker

June 30, 2025

New Response in Phase 1b Trial

June 19, 2025

Posting of Annual Report and Revised Notice of AGM

June 9, 2025

Preliminary Full Year 2024 Results

June 6, 2025

Avacta Change in Prelim Date Part 2

June 4, 2025

Board appointments

May 28, 2025

Avacta Therapeutics Announces Appointments of Industry Veterans to Board of Directors

May 28, 2025

Update on timing of preliminary results

May 27, 2025

Notice of Results

May 15, 2025

Investor Webinar

May 12, 2025

Block Listing Application to AIM

May 8, 2025

Board change

April 29, 2025

Avacta Therapeutics Presents Data from Lead pre|CISION® Candidate FAP-Dox (AVA6000) at the 2025 AACR Annual Meeting

April 28, 2025

Avacta presents preclinical data at AACR

April 28, 2025

Avacta Therapeutics Presents Preclinical and Translational Data from pre|CISION® Platform Candidates at 2025 AACR Annual Meeting

April 28, 2025

Avacta presents data from lead candidate at AACR

April 28, 2025

Issue of Equity and Total Voting Rights

April 23, 2025

Avacta Quarterly Update

March 31, 2025

Avacta Provides Business Update for the First Quarter of 2025 Outlining Progress Against Strategic Objectives

March 31, 2025

Avacta Therapeutics Announces Presentations at 2025 AACR Annual Meeting

March 26, 2025

Avacta Announces Presentations at AACR

March 26, 2025

Avacta Completes Launch Diagnostics Sale

March 25, 2025

Older news releases →

Calls in 2025

Decks in 2025